CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
CXL-1427 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02157506
NCT02157506Phase 2Completed
CompareCT.gov

A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure

Bristol-Myers Squibb·interventional·Posted Jun 6, 2014·Updated Jul 31, 2019

In Brief

A Phase 2 clinical trial evaluating CXL-1427 and Placebo for Heart Failure and 2 related conditions. Completed, enrolled 70 participants across 35 sites in 5 countries.

Detailed Summary

A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Decompensated Heart Failure, Acute Heart Failure
CountriesGermany, Jordan, Poland, Russia, United States
CollaboratorsCardioxyl Pharmaceuticals, Inc

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 6, 2014
Enrollment StartJun 30, 2014
Primary CompletionMay 31, 2015
Study CompletionJul 31, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.1 years ago

Interventions

CXL-1427drug

Placebodrug